Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ACTH RF; Corticoliberin; Corticotrophin-releasing hormone; Corticotropin-releasing factor; hCRF; Human corticotropin-releasing hormone; NEU 3002; Ovine corticotrophin-releasing factor; Xerecept

Latest Information Update: 02 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Salk Institute
  • Developer Celtic Pharma
  • Class Pituitary hormone releasing hormones
  • Mechanism of Action Corticotropin-releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain oedema
  • New Molecular Entity No

Highest Development Phases

  • No development reported Brain oedema; Cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 02 Sep 2015 No recent reports on development identified - Phase-I/II for Brain oedema (In adolescents, In children) in USA (SC)
  • 02 Sep 2015 No recent reports on development identified - Preclinical for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top